OLANZAPINE; SAMIDORPHAN L-MALATE | N213378 | ALKERMES INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2026-06-18 | Active | — | |
ALKERMES, INC. et al v. MSN PHARMACEUTICALS, INC. et al 4 patentsANDA 220726olanzapine/samidorphan | D.N.J. | 2025-09-05 | Active | — |
| D. Del. | 2025-08-28 | Terminated 2025-11-03 | — | |
| D.N.J. | 2025-08-27 | Active | — | |
ALKERMES, INC. et al v. TEVA PHARMACEUTICALS, INC. 2 patentsANDA 220379olanzapine/samidorphan | D.N.J. | 2025-08-15 | Active | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$55.28
per ea
Lowest NADAC/Unit
$55.05
per ea
Brand NDCs
4
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 65757065142LYBALVI 5-10 MG TABLET | $55.28 | EA | Brand | — | 2026-06-17 |
| 65757065342LYBALVI 15-10 MG TABLET | $55.13 | EA | Brand | — | 2026-06-17 |
| 65757065242LYBALVI 10-10 MG TABLET | $55.13 | EA | Brand | — | 2026-06-17 |
| 65757065442LYBALVI 20-10 MG TABLET | $55.05 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 8778960 | Feb 13, 2032 | — | — | — | — | |
| 9119848 | Aug 30, 2031 | — | Yes | — | — | — |
| 9126977 | Aug 23, 2031 | — | — | Yes | — | |
| 9517235 | Aug 23, 2031 | — | — | — | — | |
| 10300054 | May 31, 2033 | — | — | Yes | — | |
| 10716785 | Aug 23, 2031 | — | — | — | — | |
| 11185541 | Aug 23, 2031 | — | — | — | — | |
| 11241425 | Aug 23, 2031 | — | — | — | — | |
| 11351166 | Aug 23, 2031 | — | — | — | — | |
| 11707466 | Nov 12, 2041 | — | — | Yes | — | — |
| 11793805 | Aug 23, 2031 | — | — | — | — | |
| 11951111 | Nov 12, 2041 | — | — | — | — | |
| 12194035 | Aug 23, 2031 | — | — | — | — | |
| 12390474 | Nov 12, 2041 | — | — | Yes | — | — |
| Code | Date | Status |
|---|---|---|
| NCE | May 28, 2026 | Expired |